{"id":"NCT01721044","sponsor":"Eli Lilly and Company","briefTitle":"A Moderate to Severe Rheumatoid Arthritis Study","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-06","completion":"2014-09","firstPosted":"2012-11-02","resultsPosted":"2018-01-18","lastUpdate":"2019-09-18"},"enrollment":527,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Baricitinib","otherNames":["LY 3009104","INCB 028050"]},{"type":"DRUG","name":"cDMARD","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Baricitinib 2 mg","type":"EXPERIMENTAL"},{"label":"Baricitinib 4 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor (TNF) inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic drugs (cDMARDs).","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":27.3,"sd":null},{"arm":"Baricitinib 4 mg","deltaMin":55.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":26},"locations":{"siteCount":103,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34706874","34028703","32414425","30219772","30058112","29463520","29415145","27799159","27028914"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":176},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Nausea"]}}